• 1
    Howden CW. Commentary: improving the use of gastroprotective agents among high-risk NSAID users. Aliment Pharmacol Ther 2013; 37: 1019.
  • 2
    Ho CW, Tse YK, Wu B, et al. The use of prophylactic gastroprotective therapy in patients with nonsteroidal anti-inflammatory drug- and aspirin-associated ulcer bleeding: a cross-sectional study. Aliment Pharmacol Ther 2013; 37: 81924.
  • 3
    Valkhoff VE, van Soest EM, Masclee GM, et al. Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal – a 617,400-patient study. Aliment Pharmacol Ther 2012; 36: 7909.
  • 4
    Barozzi N, Tett SE. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing. Clin Ther 2009; 31: 84961.
  • 5
    Chan FK. Editorial: single-tablet ibuprofen/double-dose famotidine for reduction of gastric and duodenal ulcers (REDUCE Trials): what can be reduced? Am J Gastroenterol 2012; 107: 3878.